Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrome.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2028-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates a non-pharmacological treatment approach for Postural Orthostatic Tachycardia Syndrome (POTS), a disorder of the autonomic nervous system characterized by an excessive increase in heart rate upon standing. POTS is commonly associated with symptoms such as dizziness, fatigue, cognitive difficulties, sleep disturbances, as well as anxiety and depression, which significantly impair quality of life.

This randomized, controlled clinical trial aims to evaluate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with slow-paced diaphragmatic breathing (at 0.1 Hz) provides greater therapeutic benefit compared to taVNS alone or sham stimulation.

A total of 100 participants will be recruited and randomly assigned to one of four groups (25 per group):

taVNS with slow-paced breathing,

taVNS with spontaneous (normal) breathing,

sham taVNS with slow-paced breathing, or

sham taVNS with spontaneous breathing.

Participants will perform the intervention daily at home for a duration of 12 weeks. Medical and psychological assessments will be conducted before and after the intervention, including measurements of heart rate, inflammatory cytokines, and patient-reported outcomes on sleep, mood, and quality of life.

The study is conducted at the Center for Public Health, Medical University of Vienna, and is open to individuals diagnosed with POTS, including those with coexisting Post-COVID-19 syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS)

NCT04632134

Orthostatic Intolerance Postural Tachycardia Syndrome Syncope, Postural +2 more

UNKNOWN NA

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

NCT03930914

Postural Orthostatic Tachycardia Syndrome

COMPLETED NA

Tragus Stimulation for POTS Treatment

NCT07163130

Postural Orthostatic Tachycardia Syndrome (POTS)

NOT_YET_RECRUITING NA

Transdermal Vagal Stimulation for POTS

NCT02281097

Postural Orthostatic Tachycardia Syndrome

ACTIVE_NOT_RECRUITING NA

VNS for Long-COVID-19

NCT05630040

Post-COVID-19 Syndrome Postural Tachycardia Syndrome Dysautonomia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Postural Orthostatic Tachycardia Syndrome (POTS) is a disorder of the autonomic nervous system characterized by an excessive increase in heart rate (≥30 bpm) within 10 minutes of standing, without a significant drop in blood pressure. Affected individuals frequently suffer from fatigue, dizziness, palpitations, cognitive dysfunction ("brain fog"), anxiety, depression, and sleep disturbances. These symptoms significantly impair daily functioning and quality of life.

Conventional pharmacological treatments often yield limited benefit and can lead to adverse effects, especially in individuals with complex autonomic dysregulation. Non-pharmacological approaches that target the autonomic nervous system more holistically and with fewer side effects are gaining increasing scientific interest.

This randomized, controlled clinical trial aims to investigate the effects of combining transcutaneous auricular vagus nerve stimulation (taVNS) with slow-paced diaphragmatic breathing at 0.1 Hz (six breaths per minute) as an integrative therapeutic strategy for individuals with POTS.

A total of 100 participants diagnosed with POTS will be randomly assigned (1:1:1:1) into four groups (25 per group):

taVNS combined with slow-paced diaphragmatic breathing (0.1 Hz)

taVNS combined with spontaneous breathing (no guided breathing exercises)

sham taVNS combined with slow-paced diaphragmatic breathing (0.1 Hz)

sham taVNS combined with spontaneous breathing (no guided breathing exercises)

All participants will undergo standardized instruction in the use of the stimulation device and, where applicable, in breathing technique by a trained therapist. The intervention will be performed daily at home for 12 weeks. taVNS is administered for 60 minutes per session using a CE-certified medical device (Nurosym™), with stimulation parameters set at 20 Hz and 200 µs pulse width. For those in the breathing groups, the slow-paced breathing is guided via a mobile app and performed for 10 minutes in the first 4 weeks and 15 minutes in the final weeks.

To evaluate the intervention's effects, a comprehensive set of physiological and psychological parameters will be assessed before and after the 12-week intervention period, including:

Change in heart rate response to orthostatic challenge (Tilt Test)

Capnography (end-tidal CO₂ monitoring) during the Tilt Test to assess ventilatory compensation and respiratory dysregulation

Cerebral tissue oxygenation measured by near-infrared spectroscopy (NIRS) during orthostatic testing to evaluate cerebral perfusion

Heart rate variability (HRV)

Serum levels of inflammatory cytokines (TNF-α, IL-6, IL-8, CRP)

Self-reported symptom burden (Malmö POTS Symptom Score)

Sleep quality (PSQI)

Health-related quality of life (SF-36)

Psychological distress (DASS-21)

Daily activity and resting heart rate (7-day wearable device)

Handgrip strength as a marker of physical capacity

Participants will also be monitored for adherence and potential adverse events. The sham taVNS groups will use identical devices delivering subthreshold stimulation to maintain blinding.

The study is conducted at the Center for Public Health, Medical University of Vienna. Eligible participants must have a confirmed diagnosis of POTS, with or without post-COVID syndrome, and meet the study's inclusion criteria. Randomization is stratified by sex and post-COVID status to ensure balance across treatment arms.

This trial aims to determine whether the integrative approach of vagal stimulation and paced breathing can enhance autonomic regulation, improve cerebral perfusion, reduce inflammation, and improve psychological outcomes in individuals with POTS. The results may offer an evidence-based foundation for non-invasive neuromodulation in the management of autonomic disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postural Orthostatic Tachycardia Syndrome (POTS) Post-acute COVID-19 Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TVNS + Slow-Paced Breathing (TVNS+SDB)

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Group Type ACTIVE_COMPARATOR

TVNS + Slow-Paced Breathing (TVNS+SDB)

Intervention Type DEVICE

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

TVNS without Breathing Training (TVNS+NB)

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Group Type ACTIVE_COMPARATOR

TVNS without Breathing Training (TVNS+NB)

Intervention Type DEVICE

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Sham TVNS + SDB

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Group Type ACTIVE_COMPARATOR

Sham TVNS + SDB

Intervention Type DEVICE

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Sham TVNS + NB

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Group Type SHAM_COMPARATOR

Sham TVNS + NB

Intervention Type DEVICE

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TVNS + Slow-Paced Breathing (TVNS+SDB)

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Intervention Type DEVICE

TVNS without Breathing Training (TVNS+NB)

Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Intervention Type DEVICE

Sham TVNS + SDB

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Intervention Type DEVICE

Sham TVNS + NB

Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Formal diagnosis of Postural Orthostatic Tachycardia Syndrome (POTS), confirmed by clinical criteria: a sustained increase in heart rate (HR) of ≥30 bpm within 10 minutes of standing, without orthostatic hypotension.

History of POTS diagnosis for at least 6 months.

Participants with Post-acute COVID-19 syndrome may be included if they meet the formal POTS criteria. These participants will be stratified based on the presence or absence of Post-Exertional Malaise (PEM).

Stable medication for POTS (same dosage/class) for at least 4 weeks before enrollment.

Willingness and ability to provide informed consent.

Screening of Undiagnosed Participants:

Suspected POTS based on clinical symptoms (e.g., dizziness, fatigue, syncope, brain fog, palpitations, exercise intolerance) persisting ≥6 months.

Preliminary Schellong test by study team.

If criteria are met, referral to a specialist (neurology or cardiology) for diagnostic confirmation.

Inclusion only after specialist-confirmed POTS diagnosis.

Exclusion Criteria

Significant hypertension (BP \>150/100 mmHg supine or standing).

Orthostatic hypotension: drop in BP \>20 mmHg systolic or \>10 mmHg diastolic upon standing.

Recent stroke or myocardial infarction (within 6 months).

Significant immunological or hematological disorders.

Severe anemia (hematocrit \<28%).

History of vagotomy.

Pregnancy or lactation.

Inability or unwillingness to provide informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No